Presentations and Publications

Presentations

 

• EADV 2026 Late-Breaking Presentation: Bempikibart, a novel IL-7Rα antibody, produces hair regrowth that persists off treatment in severe and very severe alopecia areata: efficacy and biomarker results from the Phase 2a SIGNAL-AA Part B trial
• EADV 2026 Poster Presentation: Results for an Open-label Phase 2a Trial (SIGNAL-AA Part B) of Bempikibart, a Novel IL-7Rα Antibody in Patients with Severe or Very Severe Alopecia Areata (AA)
• AAD 2025 Late-Breaking Presentation: Initial Results From The SIGNAL-AA Study: Randomized Placebo Controlled Phase 2a Trial of a Bempikibart, Novel IL-7/TSLP Bifunctional Receptor Antagonist in Patients with Severe or Very Severe Alopecia Areata

 

Publications

 

• Development and Optimization of Bifunctional Fusion Proteins to Locally Modulate Complement Activation in Diseased Tissue
• Natural antibody and complement activation characterize patients with idiopathic nephrotic syndrome